A carregar...
Preclinical study of CC223 as a potential anti-ovarian cancer agent
Aberrant activation of mTOR contributes to ovarian cancer progression. CC223 is a novel and potent mTOR kinase inhibitor. The current study tested its activity against human ovarian cancer cells. We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5601667/ https://ncbi.nlm.nih.gov/pubmed/28938571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17753 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|